Clinical Trials Browser

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

22 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

119 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

129 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

57 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06508216 2024-07-22

COMPASS-TNBC

Phase 1/2 Recruiting

50 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05215106 2024-07-08

POP-DURVA

Phase 2 Recruiting

200 enrolled

Breast

Cerebral Palsy, Triple Negative Breast Neoplasms

NCT03199040 2024-05-28

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Phase 1 Terminated

18 enrolled 9 charts

Breast

Triple Negative Breast Neoplasms

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT02527434 2023-11-15

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase 2 Completed

64 enrolled 22 charts

Breast

Triple Negative Breast Neoplasms

NCT03982173 2023-01-26

MATILDA

Phase 2 Withdrawn

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03167619 2022-09-13

DORA

Phase 2 Completed

45 enrolled 19 charts

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03872505 2021-08-25

PANDoRA

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1 Completed

3 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

DIAMOND

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

I-SPY

BEGONIA

AMTEC IIT: Phase 2 Multiarm Study in TNBC

DB-08

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

ATRiBRAVE

PHOENIX

SYNERGY

B-IMMUNE

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

COMPASS-TNBC

POP-DURVA

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Chemo-free BRCA-targeted Neoadjuvant Strategy

Study of Tremelimumab in Patients With Advanced Solid Tumors

MATILDA

DORA

PANDoRA

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.